Fully robotic cataract surgery completes first human case

The first fully robotic cataract surgery just happened.

In April, ForSight Robotics’ JASPER platform completed a robot-assisted cataract procedure in a human patient, performed by Dr. Alexey Rapoport with Dr. Robert Ang as principal investigator at the Asian Eye Institute in Manila. The company described the event as a landmark milestone, saying the operation was executed from start to finish by the robot, marking a transition toward standardized, scalable cataract care where more patients can access treatment despite a shortage of surgeons.

ForSight frames JASPER as more than a tool for automation. The platform “assists surgeons with every step of cataract surgeries” by delivering advanced imaging, precision, and motion scaling that aim to shrink fatigue and reduce variability between procedures. In comments to The Robot Report, co-founder, president and chief medical officer Dr. Joseph Nathan explained the underlying motivation: the world faces a growing gap between the number of trained surgeons and rising patient demand for cataract treatment. The team has long argued that robotics and AI can broaden access without compromising safety, a claim the April case put to the test in a real patient.

Testing shows that the milestone hinges on two core capabilities: high fidelity imaging to map each eye’s anatomy in real time, and motion scaling that translates the surgeon’s intended micro-movements into precise robotic actions. By handling delicate steps in a cataract operation, JASPER aims to reduce variability across operators, a factor that historically contributes to outcomes differences between surgeons and clinics. The company reports that the procedure was carried out from planning through completion, underscoring the platform’s potential to shift cataract care from specialty centers toward broader adoption.

From an engineering and operations standpoint, the event illustrates both the feasibility and the practical hurdles of moving from lab demonstrations to clinical reality. The robot’s success rests on robust imaging pipelines, reliable instrument control, and seamless coordination with the surgeon who remains the clinical decision-maker. Documentation indicates the team prioritized keeping human oversight where it matters most while expanding the robot’s role in the surgical sequence. In industry terms, this is a classic transition point: proving a system can perform a complex medical task in a patient while setting the stage for broader trials, regulatory scrutiny, and eventual cost and workflow integration with eye care clinics.

Two practitioner-oriented takeaways stand out. First, the feasibility argument now rests on repeatability rather than a single data point: if JASPER reduces intraoperative variability and fatigue across multiple surgeons and patient anatomies, the platform could unlock more consistent outcomes at scale. Second, adoption will hinge on how clinics balance initial investment, training requirements, and maintenance with the promise of throughput gains and access expansion. As Nathan noted, the true metric will be whether the technology can be deployed broadly without creating new bottlenecks in imaging quality, instrument reliability, or post-operative monitoring.

Looking ahead, observers will be watching for more data from ongoing cases, longer-term patient outcomes, and how regulatory pathways shape deployment in diverse clinical settings. If the trend holds, this milestone could accelerate a transition from occasional robotic assists to routine, fully robotic cataract care in select centers, with the potential to reshape staffing models and service reach in ophthalmology.